Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
09/06/2025 12:19
June 9 (Reuters) - Formosa Pharmaceuticals Inc 6838.TW: HARROW ACQUIRES U.S. COMMERCIAL RIGHTS TO BYQLOVI™ (CLOBETASOL PROPIONATE OPHTHALMIC SUSPENSION) 0.05% FROM FORMOSA PHARMACEUTICALS HARROW: HARROW BUYS EXCLUSIVE U.S. COMMERCIAL RIGHTS FOR BYQLOVI HARROW- BYQLOVI EXPECTED TO BE AVAILABLE IN Q4 2025 Source text: ID:nPnbylNyJa Further company coverage: 6838.TW ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates